

U.S.S.N. 10/623,398

Filed: July 18, 2003

**AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT****Remarks****Response to Restriction Requirement**

1. In the Office Action mailed February 9, 2006, the claims were divided into two groups, Group I, claims 1, 2, and 4-11, drawn to a method of using a glycosaminoglycan degrading enzyme; and Group II, claims 12, 13, and 15-19, drawn to a formulation containing the enzyme.

In response, applicants elect Group I, claims 1, 2, and 4-11, without traverse.

Claims 12, 13, and 15-19 have been cancelled.

2. The Office Action also required election of a species from among a) enzymes and, b) modes of administration. In response, Applicants elect for examination chondroitinase as the species from among enzymes. Claims 1, 2, and 4-11 read on chondroitinase. Applicants elect local administration as the species for modes of administration. Claims 1, 2 and 10 read on local administration.


U.S.S.N. 10/623,398

Filed: July 18, 2003

**AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT**

Favorable consideration of claims 1, 2, and 4-11 is earnestly solicited.

Respectfully submitted,



Patrea L. Pabst  
Reg. No. 31,284

Date: March 8, 2006

PABST PATENT GROUP LLP  
400 Colony Square, Suite 1200  
1201 Peachtree Street  
Atlanta, Georgia 30361  
(404) 879-2151  
(404) 879-2160 (Facsimile)